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Abstract
Background: The identification of safe and effective alternatives to blood transfusion is a public health priority. In
sub-Saharan Africa, blood shortage is a cause of mortality and morbidity. Blood transfusion can also transmit viral
infections. Giving tranexamic acid (TXA) to bleeding surgical patients has been shown to reduce both the number
of blood transfusions and the volume of blood transfused. The objective of this study is to investigate whether
routinely administering TXA to bleeding elective surgical patients is cost effective by both averting deaths
occurring from the shortage of blood, and by preventing infections from blood transfusions.
Methods: A decision tree was constructed to evaluate the cost-effectiveness of providing TXA compared with no
TXA in patients with surgical bleeding in four African countries with different human immunodeficiency virus (HIV)
prevalence and blood donation rates (Kenya, South Africa, Tanzania and Botswana). The principal outcome
measures were cost per life saved and cost per infection averted (HIV, Hepatitis B, Hepatitis C) averted in 2007
International dollars ($). The probability of receiving a blood transfusion with and without TXA and the risk of
blood borne viral infection were estimated. The impact of uncertainty in model parameters was explored using
one-way deterministic sensitivity analyses. Probabilistic sensitivity analysis was performed using Monte Carlo
simulation.
Results: The incremental cost per life saved is $87 for Kenya and $93 for Tanzania. In Botswana and South Africa,
TXA administration is not life saving but is highly cost saving since fewer units of blood are transfused. Further, in
Botswana the administration of TXA averts one case of HIV and four cases of Hepatitis B (HBV) per 1,000 surgical
patients. In South Africa, one case of HBV is averted per 1,000 surgical patients. Probabilistic sensitivity analyses
confirmed the robustness of the model.
Conclusion: An economic argument can be made for giving TXA to bleeding elective surgical patients. In
countries where there is a blood shortage, TXA would be a cost effective way to reduce mortality. In countries
where there is no blood shortage, TXA would reduce healthcare costs and avert blood borne infections.
Background
The risks and costs associated with blood transfusions
have increased interest in the identification of safer and
cheaper alternatives. Blood sparing interventions are
particularly important in sub-Saharan African countries
due to the high prevalence of blood borne viral infec-
tions and blood shortages. In the African region, an
average of 5 units of blood per 1000 population are
donated each year compared to between 30 and 60
units in high income countries [1,2]. It has been esti-
mated that about 150,000 women die each year during
pregnancy or soon after delivery because of a shortage
of blood for transfusion [3]. Even when blood is avail-
able, it can transmit potentially fatal viral infections. It
has been estimated that in the African region, 99% of
blood is screened for HIV, 95% for HBV and 96% for
HCV [2]. The administration of the antifibrinolytic
agent tranexamic acid (TXA) could be a cost effective
way to reduce the need for blood transfusion. A recent
systematic review of randomised controlled trials
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cal patients reduces the number of transfusions by one
third and the volume of blood required per transfusion
by one unit [4]. Ongoing studies are also being con-
ducted to investigate the effectiveness of administering
TXA in cases of trauma and women with post partum
haemorrhage [5]. In countries with blood shortages, the
administration of TXA could increase the supply of
blood for those who need it. On the other hand, where
blood is readily available the administration of TXA
could, by reducing the need for transfusion, decrease
the risk of life threatening blood borne infections and
reduce costs since fewer units of blood would need to
be given (Figure 1).
This suggests that the use of TXA may have benefits
in sub-Saharan Africa, where resource constraints argue
for cost-effective alternatives to using blood products.
Nevertheless, a comprehensive literature review failed to
find any studies investigating the cost-effectiveness of
giving antifibrinolytic agents among elective surgical
patients in developing countries.
This study uses a decision analytic model to evaluate
the cost-effectiveness of using TXA to reduce the need
for blood transfusion, thus potentially reducing mortality
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Figure 1 Possible effects of administering TXA.
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infections in four African countries.
Methods
The settings
Four African countries were selected to represent a
range of blood donation rates and HIV seroprevalence
among blood donors (Table 1). South Africa has the
highest blood donation rate at 17 units of blood donated
per 1,000 inhabitants per year, whereas in Tanzania
fewer than 3 units of blood are donated per 1,000 inha-
bitants per year (Table 1) [6]. Kenya and South Africa
have a low HIV prevalence among the donor population
(1.2%, and <0.1% respectively) whereas the prevalence is
higher in Tanzania and Botswana (2.8% and 2.1%)[6].
Model
A decision-analytic model was developed in DataTM
PRO (TreeAge software Inc., MA, USA) as shown in
Figure 2. Two costs are considered in the economic ana-
lysis: the cost of blood transfusion and the cost of TXA.
The analysis did not include indirect costs such as
wages and productivity losses due to illness and death.
The model consists of two different strategies: routinely
giving TXA to surgical patients and not giving TXA [7].
The structure of the two strategies is identical, but the
associated probabilities and payoffs differ. The decision
model starts with the choice between administering or
not administering TXA to a hypothetical cohort of
1,000 bleeding surgical patients. Whichever strategy is
chosen the patient can reach the transfusion trigger and
require a blood transfusion or can be healthy without
requiring a blood transfusion (transfusion trigger not
reached). If the patient is transfused he/she can remain
healthy, can be infected (HIV, HBV, or HCV) or can
die. If a patient did not receive a clinically indicated
blood transfusion because it was not available then he/
she has a higher probability of dying. For simplicity, it is
assumed that a patient cannot be infected by more than
one viral infection. The outcomes considered in the
decision tree are: deaths of patients who could not
receive blood transfusions due to blood shortage and
the number of HIV, HCV and HBV infections.
Data on probabilities and costs are required in order
to populate the decision model. Probabilities were esti-
m a t e df r o mp u b l i s h e ds t u d i e sa n df r o ms i m p l em a t h e -
matical models reported in the following text. All the
parameters of the model, data sources and values used
are presented in Tables 1, 2 and 3 and are discussed in
greater detail in the ‘Cost’ and ‘Probability’ sections.
Because the costs and consequences included are within
ay e a ro ft r e a t m e n t ,n od i s c o unting is required. One-
way deterministic sensitivity analysis was performed in
order to estimate the impact of parameter variation on
the incremental cost-effectiveness ratio. In addition, a
probabilistic sensitivity analysis was also undertaken in
which all utilisation and outcome variables were varied.
Probabilities
The probability of a surgical patient reaching the trans-
fusion trigger and thus requiring a blood transfusion
without receiving TXA (mean probability: 0.66, range: 0-
1) was obtained from Davies et al.[ 8 ] .A c c o r d i n gt oa
recent systematic review conducted by Henry et al.[ 4 ]
the relative risk of requiring a blood transfusion follow-
ing TXA for a surgical patient is 0.61 (CI 95%: 0.54-
0.69). Thus, the probability of requiring a blood transfu-
sion after TXA administration (0.40) was estimated by
multiplying the baseline risk by the relative risk.
Due to the low rate of voluntary blood donations, less
than 52% of the blood requirement was available to be
transfused in the WHO African Region [2]. Since there
are no published data on the likelihood of adult surgical
patients receiving a blood transfusion or on the demand
and supply of units of blood during surgery in the four
countries considered in the study, the probability of
being transfused in a setting where TXA is not routinely
used was based on the WHO’s recommendations [9,10].
According to WHO [9], a blood supply of between 10-
20 whole blood units per 1,000 population will satisfy
baseline clinical demand [6,9,10]. Thus, it is assumed
that if the volume of blood donated (v) exceeds 0.01
times the population (p), there is no shortage of blood
and all surgical patients requiring a transfusion will
receive one, otherwise a shortage is assumed and only a
proportion of patients will be transfused.
Probability of receiving a blood transfusion no TXA              () / .  00 01p
With routine administration of TXA, in a situation of
blood shortage, the probability of receiving a blood
transfusion, for patients who reach the transfusion trig-
ger, increases because some patients receiving TXA may
no longer require a transfusion or will need fewer units
thus more units will be available across the proportion
of the population that needs transfusions. Thus, the
probability of receiving a transfusion (given a shortage
of blood) becomes:
Probability of receiving a blood transfusion with TXA              () ( (    /. ) )
*( / )*( / )
00 1
1
p
mn R
Where m represents mean number of units transfused
in the absence of TXA and n is the mean number of units
transfused given routine administration of TXA. Accord-
ing to Davies et al. [8] the mean number of units trans-
fused without TXA in elective surgery patients (all types
of surgery) having an allogenic blood transfusion, m,i s
3.13 (2.52-3.73). Thus, the mean number of units required
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ing from m the estimated reduction in the volume of
blood transfused (-1.12 95%CI; -1.59 -0.64)[11].
If patients require on average 3/4 as much blood fol-
lowing TXA, then 4/3 times as many can be transfused
using a fixed total number of units. R is the relative risk
of a surgical patient requiring a transfusion given rou-
tine administration of TXA (0.61 95%CI: 0.54-0.69) [4].
Thus, if half as many require transfusion following
TXA, the proportion that can be transfused doubles.
The probabilities of being transfused with and without
TXA are reported by country in Table 2. In Botswana
and South Africa, where the donation rate is relatively
high, the administration of TXA does not increase the
likelihood of being transfused. However, in countries
such as Tanzania and Kenya, which have very low dona-
tion rates, the probability more than doubled (Table 1
and 2)[6].
No studies were found that reported the probability of
death among elective surgical patients in Africa. Accord-
ing to the meta-analysis of international studies con-
ducted by Davies et al. [8] the probability of death for
elective surgical patients in high income countries
(HICs) is 0.03 (95% CI 0.00-0.21). In order to account
for the higher underlying mortality rate of the SSA
region, the HICs surgery mortality rate was adjusted
according to the following equation:
Probability of dying from surgery in SSA probability of d               ( y ying from surgery in HICs
mean probability of dying in HI
      
        

C Cs baseline mortality rate in SSA for adults
years
)(               15 60
) )
The estimated probability of dying in SSA is 0.06
[8,12]. In a one way sensitivity analysis, this value was
assumed to range between 0.04 and 0.11, with the lower
figure representing the underlying probability of dying
in sub-Saharan Africa, and the upper figure calculated
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Figure 2 Decision tree for Tranexamic acid administration in surgical setting.
Table 1 Donation rate and HIV prevalence by country
a
Country Donation
rate
b
Percentage of blood collections reactive
to HIV
Botswana 11.6 2.1
South
Africa
17.0 0.1
Tanzania 2.7 2.9
Kenya 3.3 1.2
a Source data[6]
b Donation rate per 1,000 inhabitants per year (2007 values)
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estimate [8].
Several studies conducted in SSA have shown that
between 16 to 71% of deaths from maternal haemor-
rhage are due to lack of blood [13]. Nevertheless, no
studies were found on death rates of surgical patients
in Africa who did not receive clinically indicated blood
transfusions. The only data available in the literature
come from a cohort study of adults admitted for sur-
gery in the US who refused blood transfusions for reli-
gious reasons [14]. This study estimated that the odds
of death for a patient with a postoperative Hb of ≤8g /
dl increased 2.5 times (95% CI: 1.9-3.2) for each gram
decrease in haemoglobin[14]. In SSA due to the high
risk of infections and the lack of blood, patients are
usually transfused when their haemoglobin level (Hb)
is 5 g/dl or below. Using the relationship estimated by
Carson et al. [14] a surgical patient in SSA who does
not receive a necessary blood transfusion has an esti-
mated probability of dying of 0.45% (95% CI:0.0 to
0.91).
The per-unit risk of HIV, HBV and HCV infections in
the four target countries was obtained using a risk
model developed by Jayaraman et al. [15] where the
probability of being HIV, HBV and HCV infected per
single unit of blood in each country was estimated
according to the formula:
p infection risk of infected units entering blood supply () *             i infectivity risk
risk of a subsceptible person receiving c
 
         * o ontaminated unit  
The risk of an infected unit entering the blood supply
is estimated using prevalence of infection in donors,
screening coverage and test sensitivity. The infectivity
risk is the probability of developing HIV, HBV or HCV
after receipt of a contaminated unit of blood. The risk
of a susceptible person receiving a blood transfusion is
dependent on the prevalence of infection in the recipi-
ent population.
Assuming that each unit of blood transfused comes
from a different donor, administering TXA would
reduce both the units of blood required per transfusion
and the probability Pt of acquiring HIV, HBV and HCV
infection through a blood transfusion [4,16].
Pp t
u   11 ()
Where p is the probability of being HIV, HBV or HCV
infected per unit and u is the number of units transfused
with and without TXA [16]. The average number of units
transfused (3.13 units), when TXA is not given, was taken
from the study conducted by Davies et al. [8] while the
number of units transfused, when TXA is given (2.01),
was calculated using Henry et al. [4] results on the effec-
tiveness of TXA in reducing volume of blood transfusion.
The HIV prevalence in donors was obtained from the
PEPFAR latest release [6]. Data on the HBV and HCV pre-
valence among blood donors was obtained from a sys-
tematic literature review. In Tanzania and Kenya, where
more than one estimate of HCV and HBV prevalence was
available from the literature, an average of the available
values was used to populate the model (Table 3). No data
regarding the HCV prevalence in both South Africa and
Botswana were retrieved.
Costs
All costs are reported in 2007 International dollars ($).
Two cost items are considered in the analysis: the cost
of blood transfusions and the cost of giving TXA.
The cost of providing a unit of blood in Africa from a
health and social service perspective depends on the
type of system established to provide blood transfusions
[17]. Where centralised transfusion services have been
established the final cost of producing one unit of blood
Table 3 Prevalence of HBsAg and HCV by country.
TTI prevalence
Country Reference Year HBsAg Anti HCv
Botswana [2] 2004 0.05 NA
South Africa [2] 2004 0.05 NA
Kenya [2] 2004 0.042 NA
[39] 1999 0.039 0.018
Tanzania [40] 2006 0.048 NA
[41] 2006 0.088 0.015
[42] 2007 0.053 0.055
NA: not available
Table 2 Probabilities used to populate the model
Parameters NO TXA TXA
Probability of reaching the transfusion trigger 0.66 (0-1) 0.40 (0-0.66)
Probability of being transfused Botswana 1 1
Kenya 0.33 0.86
Tanzania 0.27 0.70
South Africa 1 1
Probability of death for a surgical patient in Africa 0.06 (0.04-0.11) 0.06 (0.04-0.11)
Probability of death for anaemic surgical patients who did not receive transfusions 0.45 (0.06-0.91) 0.45 (0.06-0.91
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higher cost of recruiting, screening and distributing
blood to individual hospitals throughout the country
[17]. It has been estimated that costs associated with
donor recruitment account for half of the budget of cen-
tralised transfusion services[17]. In a hospital based ser-
vice, on the other hand, the cost of recruiting donors is
shifted to the families of the patient that donate the
blood or purchase it on the black market [17]. The cost
of one unit of blood in Kenya, which relies on a hospi-
tal-based service, was assumed to be $15.60 (in 2007
prices) [18,19] because of a lack of country-specific data.
A cost of $57.10 was assumed for Tanzania, South
Africa and Botswana as these three countries have suc-
cessfully introduced centralised blood transfusion ser-
vices with 100% of voluntary donations [1,17,18].
Administering TXA to elective surgical patients is an
inexpensive and easy intervention[20]. The time
required to administer TXA and observe the patient is
short (maximum 15 minutes) and no additional training
is required to administer the drug (IV administration is
a routine procedure for qualified nurses). Also the sup-
plies required to administerT X A( e . g .1 0m Ls y r i n g e ,
100 ml bag of saline, large gauge needle) are likely to be
available and affordable even in limited resource setting.
Thus, the assumed costs in the present analysis were $2
and $3 for TXA administration and supplies respec-
tively. The main cost item of the intervention is the
drug cost per ampoule of TXA. The cost of TXA might
vary by country and by producer [20-22]. Also the
dosage needed to prevent fibrinolysis is not well estab-
lished[4,23]. Horrow et al. [24] observed that a dose of
10 mg/kg of TXA followed by 1 mg/kg/hour is effective
in decreasing bleeding among surgical patients and that
larger doses did not provide any additional haemostatic
benefit. As a result, a fixed dose of 2 gram intravenously
infused was assumed. In previous trials, it has been
observed that this dosage would be efficacious for both
larger patients (>100 kg) but also safe in smaller patients
(<50 kg) without adverse events[25].
Overhead costs associated with storage, distribution,
and inventories were assumed to be zero. TXA is ther-
mally stable and does not require specific storage condi-
tions. Thus, storage and distribution costs per
intervention are negligible [5].
The global cost of TXA (Cyklokapron® Pfizer) was
obtained from the British National Formulary and con-
verted to 2007 $ using the purchasing power parity
exchange rate [26,27].
The overall cost of administering a dose of TXA is
estimated to be $13 (made up of a drug cost of $8, staff
time $2 and supply cost $3).
Handling of uncertainty
Univariate deterministic analyses were performed to
investigate the impact of selected model parameters on
the cost effectiveness of TXA in each of the four coun-
tries. As the probability of requiring a blood transfusion
without TXA can vary according to the type of surgery,
the age of the patient and the adoption of a restrictive
transfusion trigger, a broad range of values between 0
and 1 were explored [8]. The relative risk of requiring a
blood transfusion with TXA versus no TXA was varied
between 0.54 and 0.69 following Henry et al. [11]. The
probability of death for a surgical patient requiring and
not receiving a blood transfusion was estimated to range
between 0.75 (assuming that the patient has a Hb value
as low as 3 g/dl) and 0.15 (for patients who are moder-
ately anaemic, Hb = 7 g/dl)[14]. One way sensitivity
analysis was also performed to explore how cost effec-
tiveness changed according to the probability of death
for a surgical patient (0.04-0.11) and for the number of
units transfused to a surgical patient without TXA
(2.52-3.73) [8].
In order to account for the potential differences in
TXA prices across countries, we use a range of values
obtained from the published literature to explore the
cost-effectiveness of TXA for different TXA prices in a
one way deterministic analysis [28]. The lowest price
considered $3.13 (2007 prices), came from a study con-
ducted in Spain that estimated the effectiveness of TXA
administration during total knee arthroplasty. The high-
est value, $44 (2007 prices) was retrieved from an
American study on the use of antifibrinolytic agents in
surgery for congenital heart disease [22,29]. The cost of
a unit of blood was assumed to range between $15.60
(cost of a unit of blood in a hospital based blood system
in Africa) and $262 (cost of a unit of red cells in high
income countries)[19,30].
A further sensitivity analysis assuming no blood shortage
in any the four countries was performed to investigate the
effectiveness of TXA in preventing blood borne infection.
A probabilistic approach was adopted in order to assess
the impact of the uncertainty more accurately. The beta,
gamma and lognormal distributions were chosen for
probability, cost and relative risk parameters respectively,
following the suggestions of Briggs et al.[ 3 1 ] .M o n t e
Carlo simulations were conducted to generate 1,000 sam-
ples from the parameter probability distributions [31].
The incremental cost (ΔC), incremental effectiveness
(ΔE) and the incremental net benefit of TXA versus no
TXA were calculated for each of the Monte Carlo simu-
lations according to the following formula:[31]
Incremental net benifit INB E C      ()*   
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the outcome (e.g. lives saved). Cost-Effectiveness
Acceptability Curves (CEACs) show the probability that
the intervention is cost effective, given the range of
monetary value the policy maker is willing to pay for a
particular unit change in the outcome [31]. CEACs plot
the proportion of simulations for which the incremental
net benefit of giving TXA versus no TXA is greater
than zero (the intervention is cost effective) for a will-
ingness to pay range of $0 to $1,000.
Results
Base case analysis
The effectiveness of the intervention varies across coun-
tries and depends on the probability of receiving blood
with and without the routine use of TXA (Table 2). The
overall number of lives saved with TXA versus no TXA
is given by the difference in the number of deaths with
and without TXA per 1,000 patients. The number of
deaths with and without TXA is the is the sum of three
elements: deaths of those patients who need a blood
transfusion and do not receive it, deaths of patients who
need a blood transfusion and receive one, and deaths of
patients who did not need a transfusion (die from sur-
gery-related conditions). In Botswana and South Africa,
where every patient who needs blood is transfused, the
administration of TXA is not lifesaving. In Kenya, where
the probability of receiving a blood transfusion despite
receiving TXA is 33%, the administration of TXA saves
150 lives per 1,000 patients compared to the do-nothing
scenario (Table 4). In Tanzania, TXA is also life saving
but the effect is slightly lower with 140 lives saved.
According to the present model TXA does not prevent
blood-borne viral infections in countries where there is
a blood shortage since any blood saved from giving
TXA is reallocated to other patients. However, giving
TXA in countries where blood is not tested for all viral
infections can avert new cases of blood-borne infections.
In Botswana, the administration of TXA can avert one
H I Vc a s ea n df o u rH B Vi n f e c t i o n sp e r1 , 0 0 0p a t i e n t s
since TXA reduces both the total number of blood
transfusions administered in the country and the prob-
ability of being infected per blood transfusion. TXA did
not prevent HIV in South Africa because the probability
of acquiring HIV is very low, less than 1%, even if
patients do not receive TXA. However, based on our
model, the use of TXA can prevent one case of HBV
per 1,000 patients in this setting.
The incremental cost of administering TXA in coun-
tries where there is blood shortage is $13,000 for 1,000
patients (Table 4). Thus, the estimated incremental cost
per life saved is $87 and $93 for Kenya and Tanzania
respectively. However, in South Africa and Botswana,
where adequate availability of blood ensures access to
transfusion for every surgical patient, use of TXA could
save $59,000 per 1,000 patients since a lower number of
transfusions will be performed (Table 4).
Sensitivity analysis assuming no shortage of blood
Assuming no shortage of blood in Tanzania, the country
with the highest percentage of HIV seropositive blood
donations two HIV infections, five HBV infections and
thirty-four HCV infections are averted per 1,000 surgical
patients who received TXA compared with the no TXA
scenario. In Kenya, if blood was available for all patients,
the administration of TXA would result in the preven-
tion of four HBV infections and eighteen HCV infec-
tions per 1,000 surgical patients.
One-Way sensitivity analyses
Many parameters used in the model were based on
assumptions, or were calculated through equations,
using the limited data available from literature. Since
these parameters can vary both between and within
countries, we performed extensive one-way sensitivity
analyses to examine how the cost-effectiveness of TXA
is affected by changes in the input values (Table 5).
A ss h o w ni nT a b l e5 ,t h er e s u l t sf o rB o t s w a n aa n d
South Africa are identical. In both the countries, all
patients needing a blood transfusion receive one. In all
four countries the probability of requiring a blood trans-
fusion without TXA has the greatest impact on the cost
effectiveness of TXA. If no-one requires a transfusion,
giving TXA increases costs by $13,000 (the cost of
administering TXA to 1,000 patients). For the case in
which everyone requires a transfusion, TXA is cost sav-
ing in Botswana and South Africa (-$97,000 per 1,000
patients) and life saving in Tanzania and Kenya (incre-
mental cost per additional life saved $63 and $58).
Changes in the probability of death for an anaemic
patient who does not receive a blood transfusion also
affects model outcomes. The higher the probability of
death for those not receiving a transfusion, the lower
the incremental cost per life saved of administering
TXA on a routine basis to surgical patients. Assuming
that patients not receiving transfusions are moderately
anaemic (7 dl/g), the incremental cost per life saved of
administering TXA is $380 and $416 for Kenya and
Tanzania respectively. However, if all the patients
requiring transfusion are severely anaemic (4-3 g/dl),
this value decreases to approximately $50 per life saved
[14].
The incremental cost per life saved is also sensitive to
the cost of TXA. Assuming a cost of $3.13, the incre-
mental cost per life saved is $54 in Kenya and $59 in
Tanzania. With a TXA cost of $44, the cost per life
saved increases to $327 and $350. In both Botswana and
South Africa, TXA is always cost saving regardless of
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there is a shortage of blood, variations in the cost of the
blood do not affect the cost effectiveness of TXA since
the same amount of blood will be transfused overall.
The cost-effectiveness of administering TXA is also
relatively sensitive to changes in the probability of death
for surgical patients in SSA. Holding other variables
constant, the incremental cost per life saved increases as
the probability of death among surgical patients
increases. Ranging from $83 and $88 per life saved,
assuming a probability of death of 0.04%, to $100 and
$108 assuming a probability of death of 0.11%. Both the
Relative Risk reduction of requiring a blood transfusion
with TXA and the number of units transfused without
TXA affect the model results. However, independent of
these two parameter changes, TXA remains very cost
effective in Tanzania and Kenya and cost saving in Bots-
wana and South Africa.
Probabilistic sensitivity analysis
Figure 3 presents the results of the probabilistic sensitiv-
i t ya n a l y s i s .T h ev e r t i c a la x i ss h o w st h ep r o b a b i l i t yo f
the intervention of being cost-effective given the willing-
ness to pay (WTP) per life saved reported on the
Table 4 Cost per life saved per 1,000 surgical patients
Country Incremental cost
a Lives saved with TXA Incremental cost per life saved
Botswana -$59,000
b 0 Dominant strategy
Kenya $13,000
b 150 $87
South Africa -$59,000
b 0 Dominant strategy
Tanzania $13,000
b 140 $93
a All costs are in 2007 prices
b rounded to the nearest thousand
Table 5 One way sensitivity analyses results
Kenya Tanzania Botswana South Africa
Probability of requiring a transfusion without TXA
0% $13,000
a $13,000
a $13,000
a $13,000
a
100% $58
b $63
b -$97,000
a -$97,000
a
Probability of death for a patient not receiving transfusion
75% $380
b $416
b -$59,000
a -$59,000
a
15% $50
b $53
b -$59,000
a -$59,000
a
Cost of TXA
$3.13 $54
b $59
b -$64,000
a -$64,000
a
$44 $327
b $350
b -$23,000
a -$23,000
a
Cost of one unit of blood
$15.6 $87
b $93
b -$6,000
a -$6,000
a
$262 $87
b $93
b -$316,000
a -$316,000
a
Probability of death for a surgery patient in SSA
11% $100
b $108b -$59,000
a -$59,000
a
4% $83
b $88
b -$59,000
a -$59,000
a
RR of requiring transfusion with TXA vs. no TXA
0.54 $78
b $88
b -$64,000
a -$64,000
a
0.69 $102
b $172
b -$52,000
a -$52,000
a
Number of units transfused without TXA
2.52 $105
b $110
b $-36,000
a $-36,000
a
3.73 $74
b $81
b $-81,000
a $-81,000
a
a rounded to the nearest thousand
b Incremental cost per life saved
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Page 8 of 11horizontal axis. The probability that the intervention is
cost saving is indicated by the point where the CEAC
cuts the vertical axis since a zero value for l implies
that the policy maker places no value on lives saved.
Thus in Botswana and South Africa, routine use of TXA
is expected to be cost-saving for all of the potential
combinations of parameters considered in this analysis.
Whereas, in Kenya and Tanzania, the routine use of
TXA has a zero probability of being cost effective when
the WTP per life saved is zero; this value rises to 0.7 for
a WTP per life saved higher than $100 and reaches a
plateau above 0.9 for a WTP higher than $400.
Discussion
The routine administration of TXA in bleeding elective
surgical patients could be life saving in countries such
as Kenya and Tanzania where there is a shortage of
blood because more blood will be available for those
who need it. In countries where blood is readily avail-
able, such as South Africa and Botswana, the use of
TXA is likely to be cost saving because the savings from
reducing the number of blood transfusions needed
exceed the cost of administering TXA routinely to
bleeding surgical patients. In addition, where there is no
blood shortage, the administration of TXA decreases the
risk of transfusion-transmitted viral infections because
fewer units of blood will be transfused. Therefore, inde-
pendent of the cost-effectiveness threshold for adopting
a health care intervention, administering TXA is a
dominant strategy in countries where blood transfusions
are readily available.
There is reliable evidence from randomised controlled
trials that the administration of TXA to bleeding elec-
tive surgical patients reduces the need for blood transfu-
sions and reduces the amount of blood transfused [4].
Kenya, Botswana, Tanzania and South Africa were
selected in order to evaluateh o wt h ec o s te f f e c t i v e n e s s
of administering TXA to bleeding surgical patients var-
ies according to country-specific circumstances, specifi-
cally different blood donation rates and HIV
seroprevalence [6]. Even in countries where there is a
shortage of blood, TXA is a highly cost-effective inter-
vention. According to the Commission of Macroeco-
nomics and Health [32], in the context of developing
countries a very cost effective intervention would avert
one disability adjusted life year (DALY) for less than the
average per capita income for a given country or region.
The estimated cost per life saved is $93 and $83 in Tan-
zania and Kenya respectively. Thus, assuming that a sur-
gical patient whose life was saved due to TXA
administration survives for even one year (in perfect
health) the cost per DALY averted resulting from using
Figure 3 Cost-effectiveness Acceptability curves showing the probability that administering TXA is cost effective in the four countries.
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Page 9 of 11TXA would be well below the average per capita income
of Tanzania ($400) and Kenya ($680) [33].
However, there are important limitations to the data
used in the model and these need to be taken into
account when interpreting the findings. Several model
parameters were not available in the literature and were
estimated indirectly through equations which made sev-
eral strong assumptions. For example, it was assumed
that the blood savings arising from use of TXA would
be re-distributed among other surgical patients and not
used to treat other patient groups requiring blood trans-
fusions. Also the model did not account for intra-coun-
try variation in healthcare infrastructure. In rural areas
for instance, the probability of death for a surgical
patient and the probability of being HIV, HBV and
HCV infected may be higher as both qualified personnel
and reagents for blood screening are less likely to be
available. Another potential limitation is that the risk of
being transfused and the risk reduction driven by TXA
were taken from studies conducted in developed coun-
tries [4,8]. In particular, since the rate of preoperative
anaemia among surgical patients in SSA is higher than
in HICs, it is likely that the present study is underesti-
mating the risk of being transfused and so the potential
benefit of administering TXA. According to the meta-
analysis conducted by Henry et al.[ 4 ]T X At h e r ei sn o
reliable evidence that TXA is associated with an
increased risk of adverse events such as myocardial
infarction (RR 0.96 95%CI 0.48 to1.90), increased risk of
stroke (RR 1.25 95%CI 0.47 to 3.31) and thrombotic (RR
0.77 95%CI 0.37 to1.61) events in HICs. However, it is
unclear if this may also be the case in elective surgical
patients in SSA. Cost estimates could also have been a
source of error in our model.
The analysis did not account for the potential cost
savings for surgical patients arising from TXA adminis-
tration. For example, in those African countries, such as
Mozambique, where the cost for blood transfusion ser-
vices is recovered from the beneficiaries of the transfu-
sion, TXA administration would reduce the financial
burden for the patients [34].
The epidemiological transition in Africa is moving the
demand for surgery to conditions similar to those
observed in developed countries. Especially in the urban
areas, where the change in life expectancy and health
behaviours occur at a faster pace, the higher incidence
of non communicable diseases will contribute to an
increased demand for elective surgical procedures.
Ischemic heart disease, which is the most common
cause of cardiac surgery, now ranks 8
th among the
causes of death in SSA and is already the leading cause
of death among the elderly (>60 years) [35]. For exam-
ple, it was estimated that ischemic heart disease alone
accounted for 13660 deaths in Kenya and 27013 in
South Africa in 2002 [35]. Another cause of elective sur-
gery (e.g. hip replacement), rheumatoid arthritis, once
considered a rarity in SSA, has now become a common
disease in many countries [36].
This study evaluates the cost-effectiveness of adminis-
tering TXA among elective surgical patients in general
without distinguishing between different types of surgery
(e.g. cardiac surgery, orthopaedic surgery). This is justi-
fied since according to the meta-analysis conducted by
Henry et al. [11] TXA shows similar effectiveness in
reducing both the risk and the volume of blood trans-
fused across all the types of elective surgery. In order to
account for the difference in the risk of receiving a
blood transfusion (with and without TXA) between
types of surgery and between countries, extensive one
way sensitivity analyses have been performed.
As this was a simulation study, the data to populate
the model came from different sources and settings,
which could have affected the parameter estimates. It is
possible that TXA may also reduce mortality (RR 0.60,
95% CI: 0.32-1.12) and the risk of re-operation for
bleeding (RR 0.67, 95% CI: 0.41-1.09) [11]. Although
both these outcomes were not statistically significant, it
would be important to consider them in future studies
e v a l u a t i n gT X Ac o s te f f e c t i v e n e s s .F i n a l l y ,a sn od a t a
were found for the HCV prevalence among the donor
population in both South Africa and Botswana, it was
n o tp o s s i b l et oe s t i m a t ew h e t h e ri nt h e s et w oc o u n t r i e s
administration of TXA would lead to a reduction in the
number of HCV infections transmitted through blood
transfusions.
According to Ozgediz and Riviello [37], although sur-
gical conditions account for 11% of the global burden of
diseases, with 25 million disability-adjusted life years in
Africa, surgical procedures are “neglected diseases” in
LMICs and in particular in sub-Saharan Africa [37,38].
This study has shown that the routine administration of
TXA could be a very cost effective intervention for
reducing both the cost and the risks associated with sur-
gical procedures requiring blood transfusions in sub-
Saharan Africa [37,38]. It has been demonstrated that
TXA could be potentially lifesaving in those African
countries where there is blood shortage. Moreover, it
can also reduce cost and prevent some blood borne
infections where blood is readily available.
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